Preliminary Recommendation for the Inclusion of Rituximab 1400 mg/11.7 mL Solution for Subcutaneous (SC) Injection for the Treatment of Non-Hodgkin’s Lymphoma
Document link: Evidence Summary on Subcutaneous Rituximab for the Treatment of Non-Hodgkin’s Lymphoma (Proponents may submit appeals to hta@doh.gov.ph until 18 March 2022.) Document Preview:
Pediatric Vaccination for the prevention of COVID-19 for 5 to 11 age group
HTAC Recommends the Use of Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years Old: Guidance and Conditions for Implementation Released on 11 February 2022 Link to Evidence Summary: Pfizer-BioNTech COVID-19 Vaccine for children 5 to 11 years old COVID-19 Vaccines under Emergency Use Authorization (EUA) The Philippine Food and Drug Administration (FDA) issues an EUA for continue reading : Pediatric Vaccination for the prevention of COVID-19 for 5 to 11 age group
Preliminary Recommendation for the Inclusion of Vasopressin 20 IU/mL (IM/IV)
Document link: Preliminary Recommendation on Vasopressin (Proponents may submit appeals to hta@doh.gov.ph until 25 February 2022.) Document Preview: